Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes
Status:
Terminated
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The study will be focused on determining the integrated in-vivo mechanisms responsible for
Ramipril's effects on delaying type 2 diabetes and restoring normal (blood sugar levels)
glycemia in patients with impaired glucose tolerance.
Hypothesis - Ramipril effects will delay the onset of type 2 diabetes and restore normal
glycemia in patients with impaired glucose tolerance.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore
Collaborator:
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer